Navigation Links
Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008
Date:11/3/2008

SAN MATEO, Calif., Nov. 3 /PRNewswire/ -- Top-line preliminary data from a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented next week at a satellite symposium at the American Heart Association's (AHA) Scientific Sessions 2008 in New Orleans.

John R. Teerlink, M.D., Professor of Medicine, University of California San Francisco, will present the data from the multicenter, international Pre/RELAX-AHF study as part of a symposium entitled "Tailoring Therapy to Presentation" that will focus on new approaches to the treatment of acute heart failure. The symposium will take place from 6 a.m. CST to 8 a.m. CST on Monday, Nov. 10, in the Grand Ballroom of the Sheraton New Orleans Hotel.

According to the AHA, heart failure is a costly syndrome contributing to more than 3 million hospitalizations each year in the U.S. The great majority of patients with acute heart failure have fluid accumulation in the lungs (congestion) that causes shortness of breath and other complications. For these patients, the current standard of care includes diuretics and vasodilators. Both of these classes of agents have been associated with renal impairment, hypotension and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women. Data from a pilot study in patients with heart failure support the expectation that these effects may be beneficial in relieving the signs and symptoms of heart failure.

About Corthera

Corthera Inc. is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. Corthera has worldwide rights to develop and commercialize relaxin.

About the Satellite Symposium

Dr. Teerlink is the chair of the symposium and co-principal investigator of the Pre/RELAX-AHF study. Additional speakers will include Dr. Marco Metra, associate professor of cardiology, Department of Experimental and Applied Medicine, University of Brescia, Italy, and Dr. Gregg Fonarow, professor of medicine, UCLA School of Medicine. Dr. Metra is also co-principal investigator of the Pre/RELAX-AHF Study. Additional symposium information can be found at:
http://www.thrombo.net/tailoring-therapy/tailoring-therapy.pdf

Contact: Andreas Marathovouniotis or Ian Stone

Russo Partners

212.845.4235 or 619.814.3510

andreas.marathis@russopartnersllc.com

ian.stone@russopartnersllc.com


'/>"/>
SOURCE Corthera
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
2. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
9. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
10. Symmetry Medical Reports Preliminary Third Quarter Revenue
11. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Oxford Gene Technology ... Palette an anpassbaren SureSeq™ NGS-Panels mit dem Start ... ein schnelles und kostengünstiges Studium der Varianten bei ... Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) und ... Panel und ermöglicht eine individuelle Anpassung durch die ...
(Date:12/8/2016)... ... 08, 2016 , ... Microbial genomics leader, uBiome, joins Google, ... of just six company finalists in the Health & Medicine category. Over 1,000 ... as finalists in this year’s awards include Google, SpaceX, Oculus, and SolarCity. Individuals ...
(Date:12/8/2016)... Dec. 8, 2016 Savannah River Remediation ... and selected NewTechBio,s NT-MAX Lake & Pond ... beneficial bacteria, in conjunction with Hexa Armor/ Rhombo ... with National Pollutant Discharge Elimination System requirements. ... a steady history of elevated pH levels, above ...
(Date:12/7/2016)... ... 07, 2016 , ... A new study published in the ... treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for ... blood sampling may improve the value of a blood-based test.” The study was ...
Breaking Biology Technology:
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
(Date:6/22/2016)... June 22, 2016  The American College of Medical Genetics ... Executive Magazine as one of the fastest-growing trade shows ... at the Bellagio in Las Vegas . ... percentage of growth in each of the following categories: net ... and number of attendees. The 2015 ACMG Annual Meeting was ...
Breaking Biology News(10 mins):